Benzinga's Top Pre-Market Losers

MAP Pharmaceuticals Inc MAPP dipped 23.28% to $13.15 in the pre-market session. The US Food and Drug Administration rejected MAP Pharmaceuticals' orally inhaled treatment for migraine. Apollo Group Inc APOL moved down 6.83% to $40.2501 in the pre-market session. Apollo Group reported its Q2 earnings, excluding items, at $0.58 per share. However, analysts were expecting earnings of $0.39 per share. Expedia Inc EXPE shares fell 2.93% to $34.40 in the pre-market trading. Egencia, an Expedia company, announced its plans to acquire VIA Travel. Hatteras Financial Corp HTS dipped 2.60% to $27.31 in the pre-market session. Hatteras Financial announced its plans to sell 15 million shares in a public offering.